Yokogawa is enabling innovation and digitalization of Europe’s pharmaceutical industry; ensuring stable and reliable supply of medicines to patients.
Pharmaceutical companies must achieve:
- increased flexibility and agility through better use and monitoring of manufacturing data to improve quality management in real time
- reduced time to market
- increased process efficiency.
Improve quality management in real time
Reduced time to market
Increased process efficiency
Right first-time, and zero-waste drug manufacturing are enabled by the utilization and smart analysis of manufacturing data in real-time.
With Yokogawa products and services, we safely, securely and smartly enable higher production flexibility, quicker and more agile process implementation, improved supply chain management, and faster achievement of target yields.
Deployed on-premise, in the cloud and at the edge, our technology and know-how deliver improvement in production quality, flexibility and cost.
Yokogawa … Integrator of all; ensuring well-being of all.
Do you want to be informed of Yokogawa’s latest perspectives and innovations in the Pharma Industry?
Pharmaceutical
The pharmaceutical industry currently faces a major challenge in taking full advantage of the opportunities presented in large emerging markets. Now, more than ever, pharmaceutical companies need to introduce lean manufacturing techniques that will enhance profitability. As one of the world's leading industrial automation suppliers, Yokogawa is committed to delivering the best possible solutions for your best manufacturing practices.
Resources
A critical requirement in biopharmaceutical development is the integration and automation of process equipment and analytical instruments used in the laboratory. Bioprocess labs with multiple lab-scale bioreactors often execute cultivation experiments in parallel for research or process development purposes.
As part of a collaboration between Securecell (Zurich, SW) and Yokogawa Life Science (Tokyo, Japan), this application note demonstrates the effective use of the Lucullus® Process Information Management System (Lucullus®) to assist in the control of three Advanced Control Bioreactor Systems (BR1000) to study glucose utilization of CHO cells for optimal monoclonal antibody productivity.
The critical steps in achieving advanced process control include building an accurate digital twin of a bioreactor, validating it, and establishing communication between the bioreactor and its digital twin. Several of these steps are already mature and Yokogawa is making rapid progress toward realizing ‘smart’ bioreactors for smart manufacturing.
Yokogawa Insilico Biotechnology released its Insilico Digital Twin Factory, which can help drugmakers increase productivity and bring down manufacturing costs and time to market by potentially replacing up to 50% of the experiments needed during the process development, characterization and scale-up of biopharmaceuticals.
Downloads
Certificates
Videos
Welcome to a transformative journey in the pharmaceutical industry!
News
-
Press Release Feb 20, 2023 Yokogawa Enters into Partnership with Radial Software Group to Provide AI-powered Viewport Software Worldwide
- Giving customers a single view of all their technical data -
-
Press Release Feb 2, 2023 Yokogawa Acquires Fluence Analytics, a Pioneer in Digitalizing the Monitoring of Polymerization Reaction Processes
- Enabling continuous real-time monitoring of polymers and biopolymers -
-
Press Release Nov 2, 2021 Yokogawa Acquires Insilico Biotechnology, Developer of Innovative Bioprocess Digital Twin Technology
Enabling solutions for biopharmaceutical development and production
-
Press Release Oct 5, 2021 Yokogawa UK and Source Medical announce partnership for societal well-being
Source Medical, a leading provider of turnkey healthcare solutions and Yokogawa UK, announce a partnership that combines best in class technology and services to co-create value for the well-being of society through collaborative activities in the healthcare industry.
-
Press Release Dec 3, 2020 Yokogawa and InSphero Enter into Partnership Agreement
- Supporting drug development research through the use of HCA and three-dimensional culture models -
Looking for more information on our people, technology and solutions?
Contact Us